|
Market Closed -
Nasdaq
21:00:00 11/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 6.410 USD | +0.63% |
|
-8.45% | -49.86% |
| 08-06 | Cytosorbents Corporation, Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Cytosorbents Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Cytosorbents Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 20.14 | - | - |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -49.83% | - | - |
| Enterprise Value (EV) | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 20.14 | 20.14 | 20.14 |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -49.83% | 0% | 0% |
| P/E | -7.35x | -2.07x | -1.73x | -2.39x | -4.92x | -1.46x | -7.12x | 10.7x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.1x | 0.1x | 0.1x | 0.1x | -0x | 0.1x | -0x |
| Capitalization / Revenue | 4.22x | 1.95x | 1.59x | 1.27x | 1.08x | 0.52x | 0.46x | 0.39x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.52x | 0.46x | 0.39x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -2.63x | -25.7x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.09x | -16.5x | 8.82x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -11.4 | -15 | -12.8 | -7.6 | -2.6 | -4.4 | -0.9 | 0.6 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 43.17 | 34.69 | 36.35 | 39.2 | 37.06 | 38.88 | 44.16 | 51.6 |
| EBITDA 1 | -15.81 | -26.84 | -26.05 | -11.46 | -13.3 | -7.667 | -0.7823 | - |
| EBIT 1 | -22.74 | -31.52 | -31.21 | -16.79 | -14.24 | -9.639 | -1.219 | 2.284 |
| Net income 1 | -24.56 | -32.81 | -28.51 | -20.72 | -8.198 | -13.91 | -2.772 | 2.284 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 83.800 | 31.000 | 22.200 | 18.200 | 12.784 | 6.410 | 6.410 | 6.410 |
| Nbr of stocks (in thousands) | 2,174 | 2,182 | 2,611 | 2,734 | 3,140 | 3,142 | - | - |
| Announcement Date | 08/03/22 | 09/03/23 | 14/03/24 | 31/03/25 | 25/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.46x | - | - | - | 20.14M | |
| 30.31x | 5.36x | 20.53x | 0.3% | 225B | |
| 33.76x | 6.12x | 19.41x | 0.7% | 141B | |
| 40.01x | 10.53x | 23.25x | -.--% | 130B | |
| 16.22x | 3.33x | 10.84x | -.--% | 62.29B | |
| 18.99x | 2.29x | 11.51x | 2.68% | 49.39B | |
| 33.34x | 6.66x | 21.06x | -.--% | 48.63B | |
| 28.62x | 5.68x | 19.3x | 0.7% | 41.42B | |
| 71.49x | 6.83x | 20.81x | -.--% | 40.12B | |
| 18.7x | 5.21x | 13.45x | 1.22% | 31.23B | |
| Average | 29.00x | 5.78x | 17.80x | 0.62% | 76.97B | |
| Weighted average by Cap. | 32.49x | 6.18x | 19.12x | 0.48% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CTSO Stock
- Valuation Cytosorbents Corporation
Select your edition
All financial news and data tailored to specific country editions
